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Introduction {#jah31553-sec-0004}
============

Transcatheter aortic valve implantation (TAVI) is the definitive alternative option for patients with severe symptomatic aortic stenosis that are considered either unsuitable or high risk for surgical aortic valve replacement.[1](#jah31553-bib-0001){ref-type="ref"}, [2](#jah31553-bib-0002){ref-type="ref"} Preimplantation balloon aortic valvuloplasty (BAV) is a standard procedure during TAVI. Predilation BAV creates fractures of calcified leaflets and increases leaflet flexibility, thereby facilitating delivery of the TAVI catheter across the aortic valve and enhancing prosthesis implantation and expansion within the calcified aortic valve annulus. Importantly, it has been speculated that fewer embolic events and/or less hemodynamic instability may occur if TAVI is performed without preimplantation BAV. Nonetheless, there is also a concern that omitting preimplantation BAV may result in the need for more postimplant BAV postdilation and possible associated complications. Notably, this approach has been proposed only in single‐center studies with relatively small sample sizes; therefore, the benefits of TAVI without preimplantation BAV may be overestimated and subject to significant selection biases. We sought to undertake a systematic review and meta‐analysis to study the clinical outcomes associated with TAVI procedures performed with and without preimplantation BAV to gain insight into optimal practice during TAVI procedures.

Methods {#jah31553-sec-0005}
=======

Eligibility Criteria {#jah31553-sec-0006}
--------------------

We included studies that evaluated patients who underwent TAVI with and without preimplantation (procedural) BAV for predilation. Studies included in the meta‐analysis had to be parallel group in design, with one group having TAVI with preimplantation BAV and the other having TAVI without preimplantation BAV. We also included single‐arm studies that evaluated the feasibility of performing TAVI without preimplantation BAV. In terms of outcomes, included studies must have evaluated procedural or device success and ≥1 of the following events: need for postimplantation balloon postdilation, valve embolization, need for a second valve, vascular complications, bleeding, neurological events (stroke or transient ischemic attack), acute kidney injury, permanent pacemaker implantation, significant residual aortic regurgitation or paravalvular leakages (PVLs), and mortality. Early safety end point, if available, was reported in accordance to Valve Academic Research Consortium (VARC‐2) definitions[3](#jah31553-bib-0003){ref-type="ref"}: all‐cause mortality (at 30 days), all stroke (disabling and nondisabling), life‐threatening bleeding, acute kidney injury stage 2 or 3 (including renal replacement therapy), coronary artery obstruction requiring intervention, major vascular complication, valve‐related dysfunction requiring repeat procedure (BAV, TAVI, or surgical valve replacement). The reporting of outcomes had to include either crude events in each group or any risk or odds estimate (relative risk \[RR\], hazard ratio, odds ratio) with a 95% CI. There was no restriction based on the design of the study or the duration of follow‐up. We excluded reports in which BAV may have been performed weeks or months before TAVI (so‐called bridge‐to‐TAVI procedure) and isolated case reports, reviews, and editorials.

Search Strategy {#jah31553-sec-0007}
---------------

We conducted a search of Medline and Embase from conception to September 20, 2015, using OvidSP (Ovid Technologies). The following exact search terms were used: ("transcatheter aortic valve implantation" OR "TAVI" OR "transcatheter aortic valve replacement" OR "TAVR") AND ("Balloon aortic valvuloplasty"). There was no restriction based on language of study, and abstracts and unpublished studies were included. The references of the included studies and relevant reviews were checked for additional studies. A flow diagram is provided following the Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA) (Figure [1](#jah31553-fig-0001){ref-type="fig"}).

![Flow diagram based on the Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA). BAV indicates balloon aortic valvuloplasty; TAVI, transcatheter aortic valve implantation.](JAH3-5-e003191-g001){#jah31553-fig-0001}

Institutional review board approval and patient consent were not required because of the nature of this study as a systematic review and meta‐analysis.

Study Selection {#jah31553-sec-0008}
---------------

Two reviewers (R.B. and C.S.K.) independently checked all titles and abstracts for studies that met the inclusion criteria. The full reports of potentially relevant studies were retrieved, and data were independently extracted on study design, participant characteristics, treatment groups, outcome events, follow‐up, and results. Any discrepancies between reviewers were resolved by consensus after consulting a third reviewer (M.A.M.).

Quality Assessment {#jah31553-sec-0009}
------------------

Risk of bias was assessed by considering ascertainment of treatment groups, ascertainment of outcomes, loss to follow‐up, and consideration of potential confounders in the data analysis. Publication bias was assessed using funnel plots if there were \>10 studies in a meta‐analysis and no evidence of substantial statistical heterogeneity.[4](#jah31553-bib-0004){ref-type="ref"}

Data Analysis {#jah31553-sec-0010}
-------------

We used RevMan (version 5.1.7; Nordic Cochrane Centre) to perform random‐effects meta‐analysis using the Mantel--Haenszel method to determine pooled risk ratios for dichotomous data. The I^2^ statistic was used to assess the consistency among studies, with I^2^\<25% considered low, I^2^=50% considered moderate, and I^2^\>75% considered high heterogeneity. If data or studies for meta‐analysis were insufficient, we pooled the studies using a weighted average or performed a narrative synthesis of studies that were too heterogeneous to pool. Sensitivity analyses were further performed according to the access site and type of valve for meta‐analysis.

Results {#jah31553-sec-0011}
=======

Study Population {#jah31553-sec-0012}
----------------

A total of 16 studies[5](#jah31553-bib-0005){ref-type="ref"}, [6](#jah31553-bib-0006){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [10](#jah31553-bib-0010){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [12](#jah31553-bib-0012){ref-type="ref"}, [13](#jah31553-bib-0013){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"}, [15](#jah31553-bib-0015){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"}, [20](#jah31553-bib-0020){ref-type="ref"} including 1395 patients fulfilled the inclusion criteria (Figure [1](#jah31553-fig-0001){ref-type="fig"}). The sample size, age, sex, hemodynamic echocardiographic data, predicted operative mortality risk evaluation scores, and some of the baseline characteristics are described in Table [1](#jah31553-tbl-0001){ref-type="table-wrap"}. Among the studied populations, TAVI was performed without preimplantation BAV in 721 patients and with preimplantation BAV in 674 patients. The mean age was 81.3 years, and 49.6% of participants were female in 14 studies that reported both age and sex.[5](#jah31553-bib-0005){ref-type="ref"}, [6](#jah31553-bib-0006){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"}, [15](#jah31553-bib-0015){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"}, [20](#jah31553-bib-0020){ref-type="ref"} The balloon‐expandable Edwards SAPIEN XT or SAPIEN 3 valve was implanted in 10 studies[6](#jah31553-bib-0006){ref-type="ref"}, [10](#jah31553-bib-0010){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [12](#jah31553-bib-0012){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"}, [20](#jah31553-bib-0020){ref-type="ref"} including 793 patients, and the self‐expandable Medtronic CoreValve was used in 7 studies[5](#jah31553-bib-0005){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [13](#jah31553-bib-0013){ref-type="ref"}, [15](#jah31553-bib-0015){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"} including 602 patients. One study included both types of bioprostheses.[17](#jah31553-bib-0017){ref-type="ref"} Access was transfemoral, exclusively, in 8 studies[5](#jah31553-bib-0005){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [12](#jah31553-bib-0012){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [20](#jah31553-bib-0020){ref-type="ref"}; transfemoral, trans‐subclavian, or direct aortic in 4 studies[9](#jah31553-bib-0009){ref-type="ref"}, [10](#jah31553-bib-0010){ref-type="ref"}, [13](#jah31553-bib-0013){ref-type="ref"}, [15](#jah31553-bib-0015){ref-type="ref"}; transapical in 3 studies[6](#jah31553-bib-0006){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}; and transfemoral or transapical access in 1 study.[19](#jah31553-bib-0019){ref-type="ref"} There were 4 prospective cohort studies,[5](#jah31553-bib-0005){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [10](#jah31553-bib-0010){ref-type="ref"} 4 cohort studies,[6](#jah31553-bib-0006){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [13](#jah31553-bib-0013){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"} 3 retrospective cohort studies,[11](#jah31553-bib-0011){ref-type="ref"}, [12](#jah31553-bib-0012){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"} 2 case‐matched studies,[15](#jah31553-bib-0015){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"} 2 case--control studies,[14](#jah31553-bib-0014){ref-type="ref"}, [20](#jah31553-bib-0020){ref-type="ref"} and 1 propensity‐matched study.[16](#jah31553-bib-0016){ref-type="ref"}

###### 

Characteristics of the Study Population

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study and Year of Publication                                 Without BAV                                 Age Female   Mean Gradient AVA (cm^2^) LVEF                       EuroSCORE STS‐PROM                             With BAV                                     Age Female   Mean Gradient AVA (cm^2^) LVEF                       EuroSCORE STS‐PROM                            Differences Between Baseline Characteristics
  ------------------------------------------------------------- ------------------------------------------- ------------ ---------------------------------------------------- ---------------------------------------------- -------------------------------------------- ------------ ---------------------------------------------------- --------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Grube et al[5](#jah31553-bib-0005){ref-type="ref"} 2011       60                                          80.1±6.4\    47.8±15.5\                                           23.3±15.2\                                     ---                                          ---          ---                                                  ---                                           ---
                                                                                                            53.3%        0.66±0.2\                                            NA                                                                                                                                                                                                          
                                                                                                                         NA                                                                                                                                                                                                                                                               

  Wendler et al[6](#jah31553-bib-0006){ref-type="ref"} 2012     6                                           82±3\        49±5\                                                30±12\                                         ---                                          ---          ---                                                  ---                                           ---
                                                                                                            33%          0.6±0.18\                                            NA                                                                                                                                                                                                          
                                                                                                                         NA                                                                                                                                                                                                                                                               

  Mendiz et al[7](#jah31553-bib-0007){ref-type="ref"} 2013      51                                          79±8\        80±22 (peak)\                                        20±15\                                         ---                                          ---          ---                                                  ---                                           ---
                                                                                                            65%          0.7±0.2\                                             NA                                                                                                                                                                                                          
                                                                                                                         56±10%                                                                                                                                                                                                                                                           

  Rück et al[8](#jah31553-bib-0008){ref-type="ref"} 2013        78                                          NA           NA                                                   19\                                            ---                                          ---          ---                                                  ---                                           ---
                                                                                                                                                                              NA                                                                                                                                                                                                          

  Fiorina et al[9](#jah31553-bib-0009){ref-type="ref"} 2014     55                                          83±7\        44±13\                                               27±18\                                         45                                           83±8\        48±16\                                               22±14\                                        Indexed AVA, *P*=0.09STS score, *P*=0.03Prior MI 20% no‐BAV vs 6% in BAV, *P*=0.05
                                                                                                            51%          0.39±0.1[\*](#jah31553-note-0002){ref-type="fn"}\    10±8[\*](#jah31553-note-0002){ref-type="fn"}                                                44%          0.36±0.1[\*](#jah31553-note-0002){ref-type="fn"}\    7±4[\*](#jah31553-note-0002){ref-type="fn"}   
                                                                                                                         49±13%                                                                                                                                                        49±13%                                                                                             

  Davies et al[10](#jah31553-bib-0010){ref-type="ref"} 2014     12                                          83±3\        56±19 (peak)\                                        23±12\                                         ---                                          ---          ---                                                  ---                                           ---
                                                                                                            50%          0.7±0.2\                                             6±3                                                                                                                                                                                                         
                                                                                                                         56±19%                                                                                                                                                                                                                                                           

  Conradi et al[11](#jah31553-bib-0011){ref-type="ref"} 2014    50                                          78±8\        28±14\                                               21±14\                                         50                                           81±7\        31±17\                                               23±13\                                        Similar
                                                                                                            46%          0.9±0.4\                                             8±7                                                                                         52%          0.8±0.2\                                             8±5                                           
                                                                                                                         NA                                                                                                                                                            NA                                                                                                 

  Aggarwal et al[12](#jah31553-bib-0012){ref-type="ref"} 2014   52                                          NA           NA                                                   NA                                             61                                           NA           NA                                                   NA                                            NA

  Giustino et al[13](#jah31553-bib-0013){ref-type="ref"} 2014   73                                          NA           NA                                                   NA                                             133                                          NA           NA                                                   NA                                            Similar

  Möllmann et al[14](#jah31553-bib-0014){ref-type="ref"} 2014   26                                          81.6±6.5\    36.0±17.3[\*](#jah31553-note-0002){ref-type="fn"}\   24.6±8.7\                                      30                                           82.2±5.4\    48.5±17.7[\*](#jah31553-note-0002){ref-type="fn"}\   21.4±12.1\                                    LVEF 55% (IQR 35.0--60.0%) in non‐BAV vs 60% (IQR 53.8--65.0%) in BAV group, *P*=0.01Mean gradient, *P*=0.01
                                                                                                            42.3%        0.7±0.2\                                             6.2±2.7                                                                                     43.3%        0.6±0.2\                                             6.2±3.1                                       
                                                                                                                         55%[\*](#jah31553-note-0002){ref-type="fn"}                                                                                                                   60%[\*](#jah31553-note-0002){ref-type="fn"}                                                        

  Kochman et al[15](#jah31553-bib-0015){ref-type="ref"} 2014    8                                           78.1±8.4\    46.0±14.1\                                           20±6\                                          16                                           83.3±3.7\    55.9±12.0\                                           19±7\                                         Similar
                                                                                                            50%          0.58±0.15\                                           NA                                                                                          31.3%        0.59±0.17\                                           NA                                            
                                                                                                                         38.4%                                                                                                                                                         46.8%                                                                                              

  Kempfert et al[16](#jah31553-bib-0016){ref-type="ref"} 2015   40                                          79\          42\                                                  NA\                                            40                                           80\          40\                                                  NA\                                           Differences were observed between the no‐BAV and BAV groups before adjustment for variables male sex (52% vs 70%, *P*=0.05) and stroke (23% vs 7%, *P*=0.01). The cohorts were similar after propensity score matching.
                                                                                                            30%          NA\                                                  7.62                                                                                        30%          NA\                                                  7.22                                          
                                                                                                                         52%                                                                                                                                                           51%                                                                                                

  Islas et al[17](#jah31553-bib-0017){ref-type="ref"} 2015      79[§](#jah31553-note-0005){ref-type="fn"}   82.4±5.5\    47.3±14.7\                                           18.6±9.8\                                      170[‡](#jah31553-note-0004){ref-type="fn"}   82.8±5.7\    50.1±17.7\                                           17.9±9.6\                                     Similar
                                                                                                            65.7%        0.6±0.2\                                             NA                                                                                          64.7%        0.7±0.2\                                             NA                                            
                                                                                                                         56.9±12.5%                                                                                                                                                    58.7±13.4%                                                                                         

  Conradi et al[18](#jah31553-bib-0018){ref-type="ref"} 2015    26                                          81.3±6.3\    38±14\                                               15±13\                                         26                                           81.7±5.2\    42±17\                                               15±12\                                        Similar
                                                                                                            61.5%        0.8±0.2\                                             6±3                                                                                         61.4%        0.7±0.2\                                             5±2                                           
                                                                                                                         19% ≤45%[†](#jah31553-note-0003){ref-type="fn"}                                                                                                               15% ≤45%[†](#jah31553-note-0003){ref-type="fn"}                                                    

  Wong et al[19](#jah31553-bib-0019){ref-type="ref"} 2015       50                                          84.3±6.6\    44±13\                                               NA\                                            71                                           84.4±7.5\    51±14\                                               NA\                                           In the transfemoral BAV group, smoking was 42% vs 68% in transapical no‐BAV (*P*=0.005), peripheral vascular disease was 20% vs 38% in transapical no‐BAV (*P*=0.03). AV calcification tended to be higher (*P*=0.07) in the transfemoral BAV vs the transapical no‐BAV group. Conversely, the transapical no‐BAV tended to have more (*P*=0.06) porcelain aorta than the transfemoral BAV group.
                                                                                                            58%          0.7±0.2\                                             8.5±4.6                                                                                     46%          0.7±0.2\                                             9.4±5.3                                       
                                                                                                                         50±14%                                                                                                                                                        49±15%                                                                                             

  Bijuklic et al[20](#jah31553-bib-0020){ref-type="ref"} 2015   55                                          82.9±6.8\    40.0±12.7\                                           21.4±15.1\                                     32                                           83.8±5.2\    40.5±13.4\                                           23.7±16.0\                                    Similar
                                                                                                            47.3%        0.71±0.2\                                            NA                                                                                          56.2%        0.71±0.2\                                            NA                                            
                                                                                                                         53.0±13.8%                                                                                                                                                    57.2±11.9%                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are expressed as number of patients for no‐BAV (without preimplantation BAV) and BAV (with preimplantation BAV). Values are expressed as mean±SD for age and mean gradient (mm Hg). AV indicates aortic valve; AVA, aortic valve area; BAV, balloon aortic valvuloplasty; IQR, interquartile range; Log‐EuroSCORE, logistic European system for cardiac operative risk evaluation; LVEF, left ventricle ejection fraction; MI, myocardial infarction; NA, not available; STS‐PROM, Society of Thoracic Surgeons Score for Prediction of Mortality.

\*Difference was encountered.

^†^Edwards SAPIEN XT, n=51; Medtronic CoreValve, n=28.

^‡^Edwards SAPIEN XT, n=115; Medtronic CoreValve, n=55.

^§^Percentage of patients with LVEF ≤45%.

Study Designs and Quality Assessment {#jah31553-sec-0013}
------------------------------------

Study design, time frame, country of origin, and quality assessment for included studies are reported in Table [2](#jah31553-tbl-0002){ref-type="table-wrap"}. Ascertainment of outcomes varied from medical record reviews to prospective evaluation with adjudicated clinical end points. All studies contained reliable data, and there was no loss to follow‐up. Follow‐up of patients varied and included in‐hospital outcomes, clinical visits, echocardiographic assessment, and telephone calls up to 12 months from the date of implant.

###### 

Design and Quality Assessment of Included Studies

  Study and Year of Publication                                 Design; Dates; Country                                           Ascertainment of Treatment Group   Ascertainment of Outcomes                                            Loss to Follow‐up     Adjustment for Confounders
  ------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------- -------------------------------------------------------------------- --------------------- ------------------------------------------------------
  Grube et al[5](#jah31553-bib-0005){ref-type="ref"} 2011       Prospective cohort study; 2009--2010; international              Reliable                           Follow‐up by clinical visits and echocardiography                    None                  None, crude results
  Wendler et al[6](#jah31553-bib-0006){ref-type="ref"} 2012     Cohort study; unclear; United Kingdom                            Reliable                           Assessment at 30 days                                                None                  None, crude results
  Mendiz et al[7](#jah31553-bib-0007){ref-type="ref"} 2013      Prospective cohort study; May 2010 to May 2012; Argentina        Reliable                           Follow‐up by clinical visits, echocardiography and telephone calls   None                  None, crude results
  Rück et al[8](#jah31553-bib-0008){ref-type="ref"} 2013        Cohort study; started September 2012; Sweden                     Reliable                           Unclear                                                              None                  None, crude results
  Fiorina et al[9](#jah31553-bib-0009){ref-type="ref"} 2014     Prospective cohort study; June 2012 to June 2013; Italy          Reliable                           Follow‐up by clinical visits and echocardiography                    None                  None, crude results
  Davies et al[10](#jah31553-bib-0010){ref-type="ref"} 2014     Prospective cohort study; unclear; United Kingdom                Reliable                           Unclear                                                              None                  None, crude results
  Conradi et al[11](#jah31553-bib-0011){ref-type="ref"} 2014    Retrospective cohort study; May 2011 to December 2012; Germany   Reliable                           Clinical end points were adjudicated                                 None, retrospective   None, crude results
  Aggarwal et al[12](#jah31553-bib-0012){ref-type="ref"} 2014   Retrospective cohort; March 2012 to April 2014; United Kingdom   Reliable                           Unclear                                                              None, retrospective   None, crude results
  Giustino et al[13](#jah31553-bib-0013){ref-type="ref"} 2014   Cohort study; November 2007 to September 2013; Italy             Reliable                           Assessment at 30 days and 12 months                                  None                  None, crude results
  Möllmann et al[14](#jah31553-bib-0014){ref-type="ref"} 2014   Case--control study; unclear; Germany                            Reliable                           Assessment at 30 days                                                None                  None, crude results
  Kochman et al[15](#jah31553-bib-0015){ref-type="ref"} 2014    Case‐matched study; March 2010 to April 2013; Poland             Reliable                           Follow‐up by clinical visits at 30 days, 6 months and 12 months      None                  Case‐matched analysis
  Kempfert et al[16](#jah31553-bib-0016){ref-type="ref"} 2015   Propensity‐matched analysis; March 2012 to July 2013; Germany    Reliable                           Clinical follow‐up at 30 days                                        None                  Propensity‐matched analysis
  Islas et al[17](#jah31553-bib-0017){ref-type="ref"} 2015      Cohort study; January 2009 to August 2014; Spain                 Reliable                           Clinical follow‐up at 30 days                                        None                  None, crude results
  Conradi et al[18](#jah31553-bib-0018){ref-type="ref"} 2015    Case‐matched study; unclear; Germany                             Reliable                           Clinical end points were adjudicated                                 None, retrospective   Matched by logistic regression and nearest neighbors
  Wong et al[19](#jah31553-bib-0019){ref-type="ref"} 2015       Retrospective cohort; May 2012 to December 2013; United States   Reliable                           Follow‐up by clinical visits                                         None, retrospective   None, crude results
  Bijuklic et al[20](#jah31553-bib-0020){ref-type="ref"} 2015   Case--control study; unclear; Germany                            Reliable                           Follow‐up at 30 days                                                 None, retrospective   None, crude results

Association of Preimplantation BAV Versus No BAV and Outcomes {#jah31553-sec-0014}
-------------------------------------------------------------

Device type, access site, procedure‐related outcomes, and follow‐up assessment for all included studies reporting crude rate of events are summarized in Table [3](#jah31553-tbl-0003){ref-type="table-wrap"}. A pooled analysis reporting crude rates for outcomes of studies with and without preimplantation BAV according to valve type is shown in Table [4](#jah31553-tbl-0004){ref-type="table-wrap"}. Further separate analyses were performed including only studies of patients undergoing TAVI without preimplantation BAV (Table [5](#jah31553-tbl-0005){ref-type="table-wrap"}) and with preimplantation BAV (Table [6](#jah31553-tbl-0006){ref-type="table-wrap"}).

###### 

Procedure‐Related and Clinical Outcomes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study and Year of Publication                                               Type of Valve, Approach                                 Time Frame of Assessment                               Assessment Definitions   Outcomes             No‐BAV                                                 BAV
  --------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------ ------------------------ -------------------- ------------------------------------------------------ ---------------
  Grube et al[5](#jah31553-bib-0005){ref-type="ref"} 2011                     CoreValve, transfemoral                                 30 days                                                VARC                     Procedural success   58/60 (96.7)                                           NA

  Need for a second valve                                                     1/60 (1.7)                                                                                                                                                                                                          

  Conversion to surgery                                                       1/60 (1.7)                                                                                                                                                                                                          

  Postdilation                                                                10/60 (16.7)                                                                                                                                                                                                        

  Moderate/severe AR                                                          0/60 (0)                                                                                                                                                                                                            

  Myocardial infarction                                                       0/60 (0)                                                                                                                                                                                                            

  Stroke/TIA                                                                  3/60 (50)                                                                                                                                                                                                           

  Pacemaker implantation                                                      7/60 (11.7)                                                                                                                                                                                                         

  Major vascular complication                                                 6/60 (10)                                                                                                                                                                                                           

  All‐cause mortality                                                         4/60 (6.7)                                                                                                                                                                                                          

  Wendler et al[6](#jah31553-bib-0006){ref-type="ref"} 2012                   SAPIEN XT, transapical                                  30 days                                                VARC                     Procedural success   6/6 (100)                                              NA

  Postdilation                                                                0/6 (0)                                                                                                                                                                                                             

  Moderate/severe AR                                                          0/6 (0)                                                                                                                                                                                                             

  Trivial or mild AR                                                          3/6 (50)                                                                                                                                                                                                            

  Acute kidney injury                                                         1/6 (16.7)                                                                                                                                                                                                          

  All‐cause mortality                                                         0/6 (0)                                                                                                                                                                                                             

  Mendiz et al[7](#jah31553-bib-0007){ref-type="ref"} 2013                    CoreValve, transfemoral                                 12 months                                              VARC                     Device success       48/51 (94.2)                                           NA

  Need for bailout BAV predilation[\#](#jah31553-note-0007){ref-type="fn"}    1/51 (1.96)                                                                                                                                                                                                         

  Postdilation                                                                16/51 (31.4)                                                                                                                                                                                                        

  Moderate AR                                                                 1/51 (1.96)                                                                                                                                                                                                         

  Pacemaker implantation                                                      14/49 (28.6)                                                                                                                                                                                                        

  Major vascular complication                                                 3/51 (5.9)                                                                                                                                                                                                          

  Cardiac tamponade                                                           1/51 (1.96)                                                                                                                                                                                                         

  Conversion to surgery                                                       1/51 (1.96)                                                                                                                                                                                                         

  Stroke                                                                      1/51 (1.96)                                                                                                                                                                                                         

  Combined safety end point                                                   8/51 (15.7)                                                                                                                                                                                                         

  30‐day mortality                                                            2/51 (3.9)                                                                                                                                                                                                          

  7‐month (median time) mortality                                             7/51 (13.7)                                                                                                                                                                                                         

  Rück et al[8](#jah31553-bib-0008){ref-type="ref"} 2013                      CoreValve, transfemoral                                 In hospital or 30 days                                 Unclear                  Procedural success   77/78 (98.7)                                           NA

  Need for bailout BAV predilation[\#](#jah31553-note-0007){ref-type="fn"}    1/78 (1.3)                                                                                                                                                                                                          

  Postdilation                                                                19/78 (24.4)                                                                                                                                                                                                        

  Need for a second valve                                                     14/78 (17.9)                                                                                                                                                                                                        

  Moderate AR                                                                 11/78 (14.1)                                                                                                                                                                                                        

  Severe AR                                                                   0/78 (0)                                                                                                                                                                                                            

  Myocardial infarction                                                       0/78 (0)                                                                                                                                                                                                            

  Stroke                                                                      0/78 (0)                                                                                                                                                                                                            

  Pacemaker implantation                                                      20/78 (25.6)                                                                                                                                                                                                        

  30‐day mortality                                                            5/78 (6.4)                                                                                                                                                                                                          

  Fiorina et al[9](#jah31553-bib-0009){ref-type="ref"} 2014                   CoreValve, transfemoral or direct aortic                30 days                                                VARC‐2                   Device success       47/55 (85.5)[\*](#jah31553-note-0008){ref-type="fn"}   29/45 (64.4)

  Need for bailout BAV predilation[\#](#jah31553-note-0007){ref-type="fn"}    1/55 (1.8)                                              ---                                                                                                                                                         

  Need for a second valve                                                     2/55 (3.6)                                              2/45 (4.4)                                                                                                                                                  

  Moderate or severe PVL                                                      5/55 (9.1)                                              15/45 (33)[\*\*](#jah31553-note-0008){ref-type="fn"}                                                                                                        

  Postdilation                                                                19/55 (34.5)                                            23/45 (51.1)[¶](#jah31553-note-0008){ref-type="fn"}                                                                                                         

  Myocardial infarction                                                       0/55 (0)                                                0/45 (0)                                                                                                                                                    

  Stroke                                                                      0/55 (0)                                                0/45 (0)                                                                                                                                                    

  Acute kidney injury                                                         3/55 (5.5)                                              1/45 (2.2)                                                                                                                                                  

  Major vascular complication                                                 2/55 (3.6)                                              1/45 (2.2)                                                                                                                                                  

  Minor vascular complication                                                 0/55 (0)                                                4/45 (8.9)                                                                                                                                                  

  Major bleeding                                                              3/55 (5.5)                                              1/45 (2.2)                                                                                                                                                  

  Pacemaker implantation                                                      3/55 (5.5)                                              7/45 (15.6)[¶](#jah31553-note-0008){ref-type="fn"}                                                                                                          

  Safety end point                                                            8/55 (14.5)                                             4/45 (8.9)                                                                                                                                                  

  All‐cause mortality                                                         1/55 (1.8)                                              2/45 (4.4)                                                                                                                                                  

  Davies et al[10](#jah31553-bib-0010){ref-type="ref"} 2014                   SAPIEN XT, transfemoral or direct aortic                Unclear                                                Unclear                  Device success       12/12 (100)                                            NA

  Bleeding needing transfusion                                                0/12 (0)                                                                                                                                                                                                            

  Stroke                                                                      1/12 (8.3)                                                                                                                                                                                                          

  Pacemaker implantation                                                      0/12 (0)                                                                                                                                                                                                            

  All‐cause mortality                                                         0/12 (0)                                                                                                                                                                                                            

  Conradi et al[11](#jah31553-bib-0011){ref-type="ref"} 2014                  SAPIEN XT, transapical                                  30 days                                                VARC‐2                   Device success       47/50 (94)                                             43/50 (86)

  Postdilation                                                                4/50 (8)                                                2/50 (4)                                                                                                                                                    

  Need for a second valve                                                     1/50 (2)                                                1/50 (2)                                                                                                                                                    

  Conversion to surgery                                                       1/50 (2)                                                0/50 (0)                                                                                                                                                    

  Stroke                                                                      1/50 (2)                                                3/50 (6)                                                                                                                                                    

  Myocardial infarction                                                       0/50 (0)                                                0/50 (0)                                                                                                                                                    

  Major bleeding                                                              1/50 (2)                                                1/50 (2)                                                                                                                                                    

  Major access site complications                                             1/50 (2)                                                1/50 (2)                                                                                                                                                    

  Acute kidney injury                                                         1/50 (2)                                                2/50 (4)                                                                                                                                                    

  Pacemaker implantation                                                      5/50 (10)                                               4/50 (8)                                                                                                                                                    

  Early safety end point                                                      7/50 (14)                                               12/50 (24)                                                                                                                                                  

  All‐cause mortality                                                         2/50 (4)                                                5/50 (10)                                                                                                                                                   

  Aggarwal et al[12](#jah31553-bib-0012){ref-type="ref"} 2014                 SAPIEN XT and SAPIEN 3\                                 NA                                                     VARC‐2                   Device success       50/52 (96.1)                                           60/61 (98.3)
                                                                              Transfemoral                                                                                                                                                                                                        

  Moderate or severe AR                                                       3/52 (5.8)                                              3/61 (4.9)                                                                                                                                                  

  Postdilation                                                                2/52 (4.0)                                              2/61 (3.4)                                                                                                                                                  

  Procedural safety                                                           18/52 (34.6)                                            31/61 (50.8)                                                                                                                                                

  Giustino et al[13](#jah31553-bib-0013){ref-type="ref"} 2014                 CoreValve, transfemoral, direct aortic, or subclavian   30 days and 12 months                                  VARC‐2                   Device success       73/73 (100)                                            133/133 (100)

  Cardiac tamponade                                                           6/73 (8.2)[§](#jah31553-note-0008){ref-type="fn"}       3/133 (2.3)                                                                                                                                                 

  Moderate AR needing postdilation                                            36/73 (49.3)[§§](#jah31553-note-0008){ref-type="fn"}    47/133 (35.6)                                                                                                                                               

  Acute kidney injury                                                         14/73 (19.4)                                            43/133 (32.3)[‡](#jah31553-note-0008){ref-type="fn"}                                                                                                        

  30‐day all‐cause mortality                                                  4/73 (5.5)                                              4/133 (3.0)                                                                                                                                                 

  30‐day cardiovascular mortality                                             4/73 (5.5)                                              2/133 (1.5)                                                                                                                                                 

  Long‐term[†](#jah31553-note-0009){ref-type="fn"} all‐cause mortality        17/73 (23.3)                                            24/133 (17.8)                                                                                                                                               

  Long‐term[†](#jah31553-note-0009){ref-type="fn"} cardiovascular mortality   13/73 (17.6)                                            18/133 (13.3)                                                                                                                                               

  Möllmann et al[14](#jah31553-bib-0014){ref-type="ref"} 2014                 SAPIEN XT, transfemoral                                 In hospital and 30 days                                VARC‐2                   Procedural success   26/26 (100)                                            30/30 (100)

  Postdilation                                                                3/26 (11.5)                                             3/30 (10)                                                                                                                                                   

  Cardiac tamponade                                                           1/26 (3.8)                                              0/30 (0)                                                                                                                                                    

  Moderate PVL                                                                0/26 (0)                                                0/30 (0)                                                                                                                                                    

  Major vascular complication                                                 2/26 (7.7)                                              0/30 (0)                                                                                                                                                    

  Pacemaker implantation                                                      2/26 (7.7)                                              0/30 (0)                                                                                                                                                    

  Acute kidney injury                                                         1/26 (3.8)                                              0/30 (0)                                                                                                                                                    

  30‐day mortality                                                            0/26 (0)                                                3/30 (10)                                                                                                                                                   

  Kochman et al[15](#jah31553-bib-0015){ref-type="ref"} 2014                  CoreValve, transfemoral or subclavian                   12 months                                              VARC‐2                   Device success       8/8 (100)                                              15/16 (93.8)

  Postdilation                                                                3/8 (37.5)                                              2/16 (12.5)                                                                                                                                                 

  Life‐threatening bleeding                                                   1/8 (12.5)                                              0/16 (0)                                                                                                                                                    

  Major vascular complication                                                 2/8 (25)                                                6/16 (37.5)                                                                                                                                                 

  Minor vascular complication                                                 5/8 (62.5)                                              12/16 (75)                                                                                                                                                  

  Pacemaker implantation                                                      2/8 (25)                                                4/16 (25)                                                                                                                                                   

  Myocardial infarction                                                       0/8 (0)                                                 1/16 (6)                                                                                                                                                    

  Stroke                                                                      0/8 (0)                                                 0/16 (0)                                                                                                                                                    

  In‐hospital mortality                                                       0/8 (0)                                                 1/16 (6)                                                                                                                                                    

  12‐month mortality                                                          1/8 (12.5)                                              2/16 (12.5)                                                                                                                                                 

  Kempfert et al[16](#jah31553-bib-0016){ref-type="ref"} 2015                 SAPIEN XT, transapical                                  30 days                                                Unclear                  Device success       40/40 (100)                                            40/40 (100)

  Need for a second valve                                                     1/40 (2.5)                                              1/40 (2.5)                                                                                                                                                  

  Postdilation                                                                4/40 (10)                                               6/40 (15)                                                                                                                                                   

  Mild or more residual PVL                                                   4/40 (10)                                               3/40 (7.5)                                                                                                                                                  

  Stroke                                                                      0/40 (0)                                                0/40 (0)                                                                                                                                                    

  TIA                                                                         3/40 (7.5)                                              3/40 (7.5)                                                                                                                                                  

  Pacemaker implantation                                                      1/40 (2.5)                                              2/40 (5)                                                                                                                                                    

  30‐day mortality                                                            1/40 (2.5)                                              3/40 (7.5)                                                                                                                                                  

  Islas et al[17](#jah31553-bib-0017){ref-type="ref"} 2015                    SAPIEN XT (n=166) and CoreValve (n=83), transfemoral    30 days                                                VARC‐2                   Procedural success   73 (92.3)                                              153 (90.1)

  Need for a second valve                                                     3 (3.8)                                                 9 (5.3)                                                                                                                                                     

  Conversion to surgery                                                       2 (2.3)                                                 9 (5.3)                                                                                                                                                     

  Postdilation                                                                14 (17.7)                                               32 (18.8)                                                                                                                                                   

  Mild or more residual PVL                                                   3 (3.8)                                                 6 (3.5)                                                                                                                                                     

  Stroke                                                                      1 (1.2)                                                 3 (1.7)                                                                                                                                                     

  Pacemaker implantation                                                      5 (6.3)                                                 24 (14.1)[∫](#jah31553-note-0010){ref-type="fn"}                                                                                                            

  30‐day mortality                                                            2 (2.5)                                                 20 (11.8)[∫∫](#jah31553-note-0010){ref-type="fn"}                                                                                                           

  Conradi et al[18](#jah31553-bib-0018){ref-type="ref"} 2015                  SAPIEN XT and SAPIEN 3, transfemoral                    30 days                                                VARC‐2                   Device success       25/26 (96.2)                                           24/26 (92.3)

  Need for a second valve                                                     1/26 (3.8)                                              1/26 (3.8)                                                                                                                                                  

  Annular rupture                                                             0/26 (0)                                                1/26 (3.8)                                                                                                                                                  

  Postdilation                                                                0/26 (0)                                                3/26 (11.5)                                                                                                                                                 

  Myocardial infarction                                                       0/26 (0)                                                0/26 (0)                                                                                                                                                    

  Stroke                                                                      1/26 (3.8)                                              2/26 (7.7)                                                                                                                                                  

  Major or life‐threatening bleeding                                          2/26 (7.7)                                              2/26 (7.7)                                                                                                                                                  

  Major access site complications                                             2/26 (7.7)                                              3/26 (11.5)                                                                                                                                                 

  Acute kidney injury                                                         3/26 (11.5)                                             0/26 (0)                                                                                                                                                    

  Pacemaker implantation                                                      4/26 (15.4)                                             4/26 (15.4)                                                                                                                                                 

  30‐day mortality                                                            2/26 (7.7)                                              2/26 (7.7)                                                                                                                                                  

  Early safety                                                                4/26 (15.4)                                             5/26 (19.2)                                                                                                                                                 

  Wong et al[19](#jah31553-bib-0019){ref-type="ref"} 2015                     SAPIEN and SAPIEN XT, transfemoral or transapical       30 days                                                VARC‐2                   Device success       47/50 (94)                                             63/71 (88.7)

  Valve embolization                                                          1/50 (2)                                                0/71 (0)                                                                                                                                                    

  Annular rupture                                                             0/50 (0)                                                1/71 (1.4)                                                                                                                                                  

  Postdilation                                                                15/50 (30)                                              24/71 (34)                                                                                                                                                  

  Myocardial infarction                                                       0/50 (0)                                                0/71 (0)                                                                                                                                                    

  Stroke                                                                      0/50 (0)                                                2/71 (2.8)                                                                                                                                                  

  Bleeding complications                                                      4/50 (8.0)                                              2/71 (2.8)                                                                                                                                                  

  Vascular complications                                                      2/50 (4)                                                2/71 (2.8)                                                                                                                                                  

  Transfusions                                                                28/50 (56)[√](#jah31553-note-0010){ref-type="fn"}       17/71 (23.9)                                                                                                                                                

  Acute kidney injury                                                         3/50 (6)                                                2/71 (2.8)                                                                                                                                                  

  Pacemaker implantation                                                      5/50 (10)                                               4/71 (5.6)                                                                                                                                                  

  30‐day all‐cause mortality                                                  4/50 (8)                                                3/71 (4.2)                                                                                                                                                  

  Cardiac mortality                                                           3/50 (6)                                                3/71 (4.2)                                                                                                                                                  

  Composite safety                                                            7/50 (14)                                               7/71 (9.9)                                                                                                                                                  

  Bijuklic et al[20](#jah31553-bib-0020){ref-type="ref"} 2015                 SAPIEN XT and SAPIEN 3, transapical                     30 days                                                VARC‐2                   Device success       54/55 (98.2)                                           30/32 (93.5)

  Postdilation                                                                3/55 (5.5)                                              1/32 (3.1)                                                                                                                                                  

  Moderate PVL                                                                1/55 (1.8)                                              2/32 (6.5)                                                                                                                                                  

  Myocardial infarction                                                       0/55 (0)                                                0/32 (0)                                                                                                                                                    

  Stroke                                                                      3/58 (5.2)                                              1/33 (3.0)                                                                                                                                                  

  30‐day all‐cause mortality                                                  0/55 (0)                                                2/32 (2.8)                                                                                                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are expressed as the occurrence of an event or sample size and (%). VARC‐2 definitions: Device success indicates absence of procedural mortality, correct positioning of a single prosthetic heart valve into the proper anatomical position, intended performance of the prosthetic heart valve (no prosthesis--patient mismatch and mean aortic valve gradient \<20 mm Hg or peak velocity \<3 m/s and no moderate or severe prosthetic valve regurgitation). Early safety at 30 days indicates all‐cause mortality (at 30 days), all stroke (disabling and nondisabling), life‐threatening bleeding, acute kidney injury stage 2 or 3 (including renal replacement therapy), coronary artery obstruction requiring intervention, major vascular complication, valve‐related dysfunction requiring repeat procedure (BAV, TAVI or surgical aortic replacement). AR indicates aortic regurgitation; BAV, balloon aortic valvuloplasty; NA, not available; PVL, paravalvular leakage; TIA, transient ischemic attack; VARC‐2, Valve Academic Research Consortium.

^\#^Bailout BAV predilation due to difficulties in crossing the aortic valve.

\**P*=0.014, \*\**P*=0.02, ^¶^ *P*=0.09, ^§^ *P*=0.078, ^§§^ *P*=0.056, ^&ddagger;^ *P*=0.049.

^†^Median time of 429 days.

^√^ *P*\<0.001, ^∫^ *P*=0.03, ^∫∫^ *P*=0.018.

###### 

Pooled Analysis for Adverse Outcomes Without and With Preimplantation BVA According to Valve Type

  Outcome                              Studies   Cumulative   \%    Studies   Edwards SAPIEN XT or SAPIEN 3   \%   Studies   Medtronic CoreValve   \%
  ------------------------------------ --------- ------------ ----- --------- ------------------------------- ---- --------- --------------------- -----
  Device success                       16        1311/1395    94    10        823/876                         94   6         488/519               94
  Postdilation                         14        210/1177     18    9         118/864                         14   5         92/313                29
  Need for second valve                7         37/719       5     4         18/481                          4    3         19/238                8
  Conversion to surgery                4         14/460       3     2         12/349                          3    2         2/111                 2
  Moderate or severe AR/PVL            9         124/757      16    4         9/262                           3    5         115/495               23
  Mild AR/PVL                          3         19/335       6     3         19/335                          6    NA        NA                    NA
  Stroke/TIA                           12        28/1014      3     7         24/701                          3    5         4/313                 1
  Myocardial infarction                8         1/622        0.2   4         0/360                           0    4         1/262                 0.4
  Major or life‐threatening bleeding   6         17/409       4     4         12/285                          4    2         5/124                 4
  Annulus rupture                      2         2/173        1     2         2/173                           1    NA        NA                    NA
  Cardiac tamponade                    3         11/313       4     1         1/56                            2    2         10/257                4
  Acute kidney injury                  7         74/641       12    5         13/335                          4    2         61/306                20
  Pacemaker implantation               12        117/983      12    7         60/670                          9    5         57/313                18
  Major vascular complications         6         26/412       6     2         6/177                           3    4         20/235                9
  Minor vascular complications         2         21/124       17    NA        NA                              NA   2         21/124                17
  Safety composite end point           6         111/537      21    4         91/386                          24   2         20/151                13
  Mortality                            15        72/1282      6     9         49/763                          6    6         23/519                4

AR indicates aortic regurgitation; BAV, balloon aortic valvuloplasty; NA, not available; PVL, paravalvular leakage; TIA, transient ischemic attack.

###### 

Analysis for Adverse Outcomes Without Preimplantation BAV According to Valve Type

  Outcome                              Studies   Cumulative   \%   Studies   Edwards SAPIEN XT or SAPIEN 3   \%   Studies   Medtronic CoreValve   \%
  ------------------------------------ --------- ------------ ---- --------- ------------------------------- ---- --------- --------------------- ----
  Device success                       16        691/721      96   10        380/396                         96   6         311/325               96
  Postdilation                         14        112/636      18   9         45/384                          12   5         67/252                27
  Need for second valve                7         23/388       6    4         6/195                           3    3         17/193                9
  Conversion to surgery                4         5/240        2    2         3/129                           2    2         2/111                 2
  Moderate or severe AR/PVL            9         57/456       13   4         4/139                           3    5         53/317                17
  Mild AR/PVL                          3         10/125       8    3         10/125                          8    NA        NA                    NA
  Stroke/TIA                           12        14/564       2    7         10/312                          3    5         4/252                 2
  Myocardial infarction                8         0/382        0    4         0/181                           0    4         0/201                 0
  Major or life‐threatening bleeding   6         11/201       5    4         7/138                           5    2         4/63                  6
  Annulus rupture                      2         0/76         0    2         0/76                            0    NA        NA                    NA
  Cardiac tamponade                    3         8/150        5    1         1/26                            4    2         7/124                 2
  Acute kidney injury                  7         26/286       9    5         9/158                           6    2         17/128                13
  Pacemaker implantation               12        68/535       13   7         22/283                          8    5         46/252                18
  Major vascular complications         6         17/250       7    2         4/76                            5    4         13/174                7
  Minor vascular complications         2         5/63         8    NA        NA                              NA   2         5/63                  8
  Safety composite end point           6         52/284       18   4         36/178                          20   2         16/106                15
  Mortality                            15        27/669       4    9         11/344                          3    6         16/325                5

AR indicates aortic regurgitation; BAV, balloon aortic valvuloplasty; NA, not available; PVL, paravalvular leakage; TIA, transient ischemic attack.

###### 

Analysis for Adverse Outcomes With Preimplantation BAV According to Valve Type

  Outcome                              Studies   Cumulative   \%    Studies   Edwards SAPIEN XT or SAPIEN 3   \%   Studies   Medtronic CoreValve   \%
  ------------------------------------ --------- ------------ ----- --------- ------------------------------- ---- --------- --------------------- ----
  Device success                       11        620/674      92    8         443/480                         92   3         177/194               91
  Postdilation                         10        98/541       18    8         73/480                          15   2         25/61                 41
  Need for second valve                5         14/331       4     4         12/286                          4    1         2/45                  4
  Conversion to surgery                2         9/220        4     2         9/220                           4    NA        NA                    NA
  Moderate or severe AR/PVL            5         67/301       22    3         5/123                           4    2         62/178                35
  Mild AR/PVL                          2         9/210        4     2         9/210                           4    NA        NA                    NA
  Stroke/TIA                           8         14/450       3     6         14/389                          4    2         0/61                  0
  Myocardial infarction                6         1/240        0.4   4         0/179                           0    2         1/61                  2
  Major or life‐threatening bleeding   5         6/208        3     3         5/147                           3    2         1/61                  2
  Annulus rupture                      2         2/97         2     2         2/97                            2    NA        NA                    NA
  Cardiac tamponade                    2         3/163        2     1         0/30                            0    1         3/133                 2
  Acute kidney injury                  6         48/355       14    4         4/177                           2    2         44/178                25
  Pacemaker implantation               8         49/448       11    6         38/387                          10   2         11/61                 18
  Major vascular complications         4         9/162        6     2         2/101                           2    2         7/61                  6
  Minor vascular complications         2         16/61        26    NA        NA                              NA   2         16/61                 26
  Safety composite end point           5         59/253       23    4         55/208                          26   1         4/45                  9
  Mortality                            10        45/613       7     7         38/419                          9    3         7/194                 4

AR indicates aortic regurgitation; BAV, balloon aortic valvuloplasty; NA, not available; PVL, paravalvular leakage; TIA, transient ischemic attack.

In‐Hospital and 30‐Day Outcomes {#jah31553-sec-0015}
-------------------------------

Crude device success rate was reported in all studies[5](#jah31553-bib-0005){ref-type="ref"}, [6](#jah31553-bib-0006){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [10](#jah31553-bib-0010){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [12](#jah31553-bib-0012){ref-type="ref"}, [13](#jah31553-bib-0013){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"}, [15](#jah31553-bib-0015){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"}, [20](#jah31553-bib-0020){ref-type="ref"} and achieved in 94% (1311 of 1395) of patients without differences between valve types. Crude all‐cause mortality at 30 days was reported in 15 studies[5](#jah31553-bib-0005){ref-type="ref"}, [6](#jah31553-bib-0006){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [10](#jah31553-bib-0010){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [13](#jah31553-bib-0013){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"}, [15](#jah31553-bib-0015){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"}, [20](#jah31553-bib-0020){ref-type="ref"} and occurred in 6% (72 of 1282) of patients. The safety composite end point was reported in 6 studies[7](#jah31553-bib-0007){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [12](#jah31553-bib-0012){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"} and occurred in 21% (111 of 537) of patients. The crude incidence of residual moderate or severe aortic regurgitation or PVL was reported in 9 studies[5](#jah31553-bib-0005){ref-type="ref"}, [6](#jah31553-bib-0006){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [12](#jah31553-bib-0012){ref-type="ref"}, [13](#jah31553-bib-0013){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"} and occurred in 16% (124 of 757) of patients. In this regard, 4 studies used the balloon‐expandable valve[6](#jah31553-bib-0006){ref-type="ref"}, [12](#jah31553-bib-0012){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"}, [20](#jah31553-bib-0020){ref-type="ref"} with a 3% rate (9 of 262 patients), and 5 studies used the self‐expandable valve[5](#jah31553-bib-0005){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [13](#jah31553-bib-0013){ref-type="ref"} with a 23% rate (115 of 495 patients). Of note, the need for postimplantation postdilation was reported in 14[5](#jah31553-bib-0005){ref-type="ref"}, [6](#jah31553-bib-0006){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [12](#jah31553-bib-0012){ref-type="ref"}, [13](#jah31553-bib-0013){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"}, [15](#jah31553-bib-0015){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"} studies and occurred in 18% (210 of 1177) of patients; 9 studies used the balloon‐expandable valve[6](#jah31553-bib-0006){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [12](#jah31553-bib-0012){ref-type="ref"}, [13](#jah31553-bib-0013){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"} with a 14% rate (118 of 864 patients), and 6 studies used the self‐expandable valve[5](#jah31553-bib-0005){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [13](#jah31553-bib-0013){ref-type="ref"}, [15](#jah31553-bib-0015){ref-type="ref"} with a 29% rate (92 of 313 patients). The crude cerebrovascular events, including stroke or transient ischemic attack, were reported in 12 studies[5](#jah31553-bib-0005){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [10](#jah31553-bib-0010){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [15](#jah31553-bib-0015){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"}, [20](#jah31553-bib-0020){ref-type="ref"} and occurred in 3% (28/1014) of patients; 7 studies used the balloon‐expandable valve[10](#jah31553-bib-0010){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"}, [20](#jah31553-bib-0020){ref-type="ref"} with a 3% rate (24 of 701 patients), and 5 studies used the self‐expandable valve[5](#jah31553-bib-0005){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [15](#jah31553-bib-0015){ref-type="ref"} with a 1% rate (4 of 313 patients). The need for permanent pacemaker implantation was reported in 12 studies[5](#jah31553-bib-0005){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [10](#jah31553-bib-0010){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"}, [15](#jah31553-bib-0015){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"} and occurred in 12% (117 of 983) of patients; 7 studies used the balloon‐expandable valve[10](#jah31553-bib-0010){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"} with a 9% rate (60 of 670 patients), and 5 studies used the self‐expandable valve[5](#jah31553-bib-0005){ref-type="ref"}, [7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [15](#jah31553-bib-0015){ref-type="ref"} with an 18% rate (57 of 313 patients).

Importantly, meta‐analyses evaluating outcomes using strategies with and without preimplantation BAV showed no statistically significant differences. Notably, device success (RR 1.02, 95% CI 0.98--1.06, *P*=0.24), mortality (RR 0.61, 95% CI 0.32--1.14, *P*=0.12), safety composite end point (RR 0.85, 95% CI 0.62--1.18, *P*=0.34), moderate to severe PVL (RR 0.68, 95% CI 0.23--1.99, *P*=0.48), need for postimplantation postdilation (RR 0.86, 95% CI 0.66--1.13, *P*=0.28), stroke or transient ischemic attack (RR 0.72, 95% CI 0.30--1.71, *P*=0.45), permanent pacemaker implantation (RR 0.80, 95% CI 0.49--1.30, *P*=0.37), or acute kidney injury (RR 1.10, 95% CI 0.49--2.45, *P*=0.82). The remaining outcomes are shown in Tables [4](#jah31553-tbl-0004){ref-type="table-wrap"}, [5](#jah31553-tbl-0005){ref-type="table-wrap"} through [6](#jah31553-tbl-0006){ref-type="table-wrap"}.

Sensitivity Analysis {#jah31553-sec-0016}
--------------------

We conducted a sensitivity analysis for clinical outcomes with and without preimplantation BAV according to the different access sites, comparing the transfemoral with transapical and transfemoral or any other access including the direct aortic and trans‐subclavian routes (Table [7](#jah31553-tbl-0007){ref-type="table-wrap"}, Figures [2](#jah31553-fig-0002){ref-type="fig"}, [3](#jah31553-fig-0003){ref-type="fig"} through [4](#jah31553-fig-0004){ref-type="fig"}). Those who underwent TAVI without preimplantation BAV and with the transfemoral or any other access were marginally associated with more cardiac tamponade (RR 3.61, 95% CI 1.04--12.56, *P*=0.04). Studies including the transfemoral access only were associated with higher mortality among patients who underwent TAVI with preimplantation BAV (RR 0.30, 95% CI 0.11--0.82, *P*=0.02); however, this difference disappeared when analyzed as a whole access‐site sample (RR 0.61, 95% CI 0.32--1.14, *P*=0.12).

###### 

Sensitivity Analysis With Risk of Outcomes Without or With Preimplantation BAV According to Access Site

  Outcome or Subgroup                  Studies   Patients   Relative Risk (95% CI)
  ------------------------------------ --------- ---------- ------------------------
  Device success                       11        1188       1.02 (0.98--1.06)
  Transfemoral                         5         557        1.01 (0.97--1.04)
  Transapical                          2         180        1.04 (0.90--1.19)
  Transfemoral or any other access     4         451        1.09 (0.87--1.36)
  Postdilation                         10        982        0.86 (0.66--1.13)
  Transfemoral                         5         557        0.95 (0.58--1.56)
  Transapical                          2         180        0.99 (0.35--2.78)
  Transfemoral or any other access     3         245        0.87 (0.53--1.43)
  Need for a second valve              5         581        0.82 (0.34--1.98)
  Transfemoral                         2         301        0.76 (0.24--2.42)
  Transapical                          2         180        1.00 (0.14--6.94)
  Transfemoral or any other access     1         100        0.82 (0.12--5.58)
  Conversion to surgery                2         349        0.69 (0.16--2.89)
  Transfemoral                         1         249        0.48 (0.11--2.16)
  Transapical                          1         100        3.00 (0.13--71.92)
  Moderate or severe AR/PVL            4         506        0.68 (0.23--1.99)
  Transfemoral                         2         200        0.77 (0.21--2.82)
  Transfemoral or any other access     2         306        0.65 (0.13--3.39)
  Mild AR/PVL                          2         329        1.19 (0.44--3.19)
  Transfemoral                         1         249        1.08 (0.28--4.19)
  Transapical                          1         80         1.33 (0.32--5.58)
  Stroke/TIA                           6         689        0.72 (0.30--1.71)
  Transfemoral                         3         388        0.87 (0.24--3.23)
  Transapical                          2         180        0.70 (0.20--2.49)
  Transfemoral or any other access     1         121        0.28 (0.01--5.76)
  Myocardial infarction                1         24         0.63 (0.03--13.93)
  Transfemoral or any other access     1         24         0.63 (0.03--13.93)
  Major or life‐threatening bleeding   5         397        1.98 (0.76--5.18)
  Transfemoral                         1         52         1.00 (0.15--6.57)
  Transapical                          1         100        1.00 (0.06--15.55)
  Transfemoral or any other access     3         245        3.03 (0.89--10.28)
  Annulus rupture                      2         173        0.40 (0.04--3.72)
  Transfemoral                         1         52         0.33 (0.01--7.82)
  Transfemoral or any other access     1         121        0.47 (0.02--11.32)
  Cardiac tamponade                    2         262        3.61 (1.04--12.56)
  Transfemoral                         1         56         3.44 (0.15--81.09)
  Transfemoral or any other access     1         206        3.64 (0.94--14.14)
  Acute kidney injury                  6         635        1.10 (0.49--2.45)
  Transfemoral                         2         108        5.05 (0.59--43.03)
  Transapical                          1         100        0.50 (0.05--5.34)
  Transfemoral or any other access     3         427        0.98 (0.37--2.58)
  Pacemaker implantation               8         782        0.80 (0.49--1.30)
  Transfemoral                         3         357        0.79 (0.29--2.17)
  Transapical                          2         180        1.02 (0.34--3.09)
  Transfemoral or any other access     3         245        0.85 (0.32--2.25)
  Major vascular complications         4         301        1.15 (0.45--2.99)
  Transfemoral                         1         56         5.74 (0.29--114.41)
  Transfemoral or any other access     3         245        0.96 (0.35--2.63)
  Minor vascular complications         2         124        0.38 (0.03--4.92)
  Transfemoral or any other access     2         124        0.38 (0.03--4.92)
  Safety composite end point           4         434        0.85 (0.62--1.18)
  Transfemoral                         1         113        0.68 (0.44--1.07)
  Transapical                          1         100        0.58 (0.25--1.36)
  Transfemoral or any other access     2         221        1.02 (0.66--1.58)
  Mortality                            10        1075       0.61 (0.32--1.14)
  Transfemoral                         4         357        0.30 (0.11--0.82)
  Transapical                          2         180        0.38 (0.10--1.37)
  Transfemoral or any other access     4         451        1.38 (0.58--3.32)

Any other access, trans‐subclavian or direct aortic. AR indicates aortic regurgitation; BAV, balloon aortic valvuloplasty; PVL, paravalvular leakage; TIA, transient ischemic attack.

![Meta‐analyses evaluating (A) device success, (B) mortality, (C) safety composite end point, (D) need for a second valve, (E) postdilation, and (F) major or life‐threatening bleeding for patients with and without preimplantation BAV, according to access site. BAV indicates balloon aortic valvuloplasty; M‐H, Mantel--Haenszel.](JAH3-5-e003191-g002){#jah31553-fig-0002}

![Meta‐analyses evaluating the risk of (A) annulus rupture, (B) cardiac tamponade, (C) conversion to surgery, (D) major vascular complications, (E) stroke or transient ischemic attack, and (F) acute kidney injury for patients with and without preimplantation BAV, according to access site. BAV indicates balloon aortic valvuloplasty; M‐H, Mantel--Haenszel.](JAH3-5-e003191-g003){#jah31553-fig-0003}

![Meta‐analyses evaluating the risk of (A) moderate to severe paravalvular leakage, (B) pacemaker implantation, (C) minor vascular compilations, and (D) myocardial infarction for patients with and without preimplantation BAV, according to access site. BAV indicates balloon aortic valvuloplasty; M‐H, Mantel--Haenszel.](JAH3-5-e003191-g004){#jah31553-fig-0004}

We also performed sensitivity analysis according to valve type (Table [8](#jah31553-tbl-0008){ref-type="table-wrap"}, Figures [5](#jah31553-fig-0005){ref-type="fig"}, [6](#jah31553-fig-0006){ref-type="fig"} through [7](#jah31553-fig-0007){ref-type="fig"}). The self‐expandable valve tended to be associated with more cardiac tamponade (RR 3.64, 95% CI 0.94--14.14, *P*=0.06) when the procedure was performed without preimplantation BAV and became significant when analyzed with the whole sample for type of valve (RR 3.61, 95% CI 1.04--12.56, *P*=0.04).

###### 

Sensitivity Analysis With Risk of Outcomes Without or With Preimplantation BAV According to Valve Type

  Outcome or Subgroup                  Studies   Patients   Relative Risk (95% CI)
  ------------------------------------ --------- ---------- ------------------------
  Device success                       10        1101       1.02 (0.98--1.07)
  SAPIEN                               7         609        1.01 (0.98--1.04)
  CoreValve                            3         330        1.11 (0.69--1.78)
  Postdilation                         9         733        0.84 (0.62--1.14)
  SAPIEN                               7         609        0.92 (0.60--1.40)
  CoreValve                            2         124        1.17 (0.28--4.82)
  Need for a second valve              4         332        0.92 (0.27--3.12)
  SAPIEN                               3         232        1.00 (0.21--4.84)
  CoreValve                            1         100        0.82 (0.12--5.58)
  Conversion to surgery                1         100        3.00 (0.13--71.92)
  SAPIEN                               1         100        3.00 (0.13--71.92)
  Moderate or severe AR/PVL            4         506        0.68 (0.23--1.99)
  SAPIEN                               2         200        0.77 (0.21--2.82)
  CoreValve                            2         306        0.65 (0.13--3.39)
  Mild AR/PVL                          1         80         1.33 (0.32--5.58)
  SAPIEN                               1         80         1.33 (0.32--5.58)
  Stroke/TIA                           5         440        0.72 (0.28--1.84)
  SAPIEN                               5         440        0.72 (0.28--1.84)
  Myocardial infarction                1         24         0.63 (0.03--13.93)
  CoreValve                            1         24         0.63 (0.03--13.93)
  Major or life‐threatening bleeding   5         397        1.98 (0.76--5.18)
  SAPIEN                               3         273        1.63 (0.52--5.06)
  CoreValve                            2         124        3.27 (0.53--19.93)
  Annulus rupture                      2         173        0.40 (0.04--3.72)
  SAPIEN                               2         173        0.40 (0.04--3.72)
  Cardiac tamponade                    2         262        3.61 (1.04--12.56)
  SAPIEN                               1         56         3.44 (0.15--81.09)
  CoreValve                            1         206        3.64 (0.94--14.14)
  Acute kidney injury                  6         635        1.10 (0.49--2.45)
  SAPIEN                               4         329        1.93 (0.60--6.27)
  CoreValve                            2         306        0.79 (0.26--2.41)
  Pacemaker implantation               7         533        0.98 (0.56--1.72)
  SAPIEN                               5         409        1.30 (0.66--2.57)
  CoreValve                            2         124        0.56 (0.20--1.56)
  Major vascular complications         4         301        1.15 (0.45--2.99)
  SAPIEN                               2         177        2.14 (0.42--10.80)
  CoreValve                            2         124        0.83 (0.26--2.70)
  Minor vascular complications         2         124        0.38 (0.03--4.92)
  CoreValve                            2         124        0.38 (0.03--4.92)
  Safety composite end point           4         434        0.85 (0.62--1.18)
  SAPIEN                               3         334        0.79 (0.52--1.20)
  CoreValve                            1         100        1.64 (0.53--5.08)
  Mortality                            9         826        0.78 (0.41--1.48)
  SAPIEN                               6         496        0.52 (0.28--1.40)
  CoreValve                            3         330        1.15 (0.38--3.47)

SAPIEN includes SAPIEN XT and SAPIEN 3 valves. AR indicates aortic regurgitation; BAV, balloon aortic valvuloplasty; PVL, paravalvular leakage; TIA, transient ischemic attack.

![Meta‐analyses evaluating (A) device success, (B) mortality, (C) safety composite end point, (D) need for a second valve, (E) postdilation, and (F) major or life‐threatening bleeding for patients with and without preimplantation BAV, according to valve type. BAV indicates balloon aortic valvuloplasty; M‐H, Mantel--Haenszel.](JAH3-5-e003191-g005){#jah31553-fig-0005}

![Meta‐analyses evaluating the risk of (A) cardiac tamponade, (B) annulus rupture, (C) conversion to surgery, (D) stroke or transient ischemic attack, (E) major vascular complications, and (F) acute kidney injury for patients with and without preimplantation BAV, according to valve type. BAV indicates balloon aortic valvuloplasty; M‐H, Mantel--Haenszel.](JAH3-5-e003191-g006){#jah31553-fig-0006}

![Meta‐analyses evaluating the risk of (A) moderate to severe paravalvular leakage, (B) pacemaker implantation, (C) minor vascular compilations, and (D) myocardial infarction for patients with and without preimplantation BAV, according to valve type. BAV indicates balloon aortic valvuloplasty; M‐H, Mantel--Haenszel.](JAH3-5-e003191-g007){#jah31553-fig-0007}

No significant differences were found between the different access sites and valve types among the remaining analyzed variables. Importantly, neither the access site nor the valve type affected device success rate, safety composite end point, or mortality (Tables [7](#jah31553-tbl-0007){ref-type="table-wrap"} and [8](#jah31553-tbl-0008){ref-type="table-wrap"}).

Discussion {#jah31553-sec-0017}
==========

The results of this meta‐analysis show no significant differences between patients undergoing TAVI either with or without preimplantation BAV with respect to mortality, neurological events, permanent pacemaker implantation, or improvement in device success (including repeat procedure, significant residual PVL or aortic regurgitation, and the need for postimplantation postdilation).

Rationale and Adjunctive Utilities of Preimplantation BAV During TAVI {#jah31553-sec-0018}
---------------------------------------------------------------------

The pathophysiology of aortic stenosis and calcification make it reasonable to hypothesize that crossing the heavily calcified valve by the transapical antegrade approach would not require predilation.[6](#jah31553-bib-0006){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [19](#jah31553-bib-0019){ref-type="ref"} In contrast, in transfemoral or other retrograde procedures, preimplantation BAV remains important to ensure smooth crossing of the TAVI delivery system.

Notably, our results show more cardiac tamponade without BAV, although one may be cautious in interpreting results based on only 2 studies.[13](#jah31553-bib-0013){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"} Forceful pushing of the device and movement of the stiff wire inside the ventricle might cause this issue. Importantly, even if the valve is successfully crossed with the TAVI system, failure to fully expand the transcatheter valve may translate into hemodynamic instability due to leaflet incompetence, significant PVL, valve migration, or further need for postdilation with inherent risk of valve migration.[5](#jah31553-bib-0005){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [21](#jah31553-bib-0021){ref-type="ref"} In fact, some studies reported the need for bailout BAV predilation when TAVI was initially planned without preimplantation BAV.[7](#jah31553-bib-0007){ref-type="ref"}, [8](#jah31553-bib-0008){ref-type="ref"}, [9](#jah31553-bib-0009){ref-type="ref"}, [21](#jah31553-bib-0021){ref-type="ref"} Moreover, a partial balloon‐tip inflation technique was reported to facilitate crossing of the aortic valve.[10](#jah31553-bib-0010){ref-type="ref"}, [12](#jah31553-bib-0012){ref-type="ref"}

Coronary ostia \<10 to 11 mm from the aortic annulus represent a hazard for coronary obstruction,[22](#jah31553-bib-0022){ref-type="ref"}, [23](#jah31553-bib-0023){ref-type="ref"} especially in narrow, tubular, or porcelain aortic roots exhibiting longitudinal remodeling.[22](#jah31553-bib-0022){ref-type="ref"}, [24](#jah31553-bib-0024){ref-type="ref"} In these cases, simultaneous aortogram at the time of BAV is helpful to assess the behavior of the heavily calcified aortic leaflets, especially the left leaflet toward the left main coronary artery.[9](#jah31553-bib-0009){ref-type="ref"}, [22](#jah31553-bib-0022){ref-type="ref"} Finally, performing preimplantation BAV also allows confirmation of reliable pacing‐wire capture. In the case of capture failure, albeit rare, it is preferable to deal with this issue during BAV rather than during balloon‐expandable valve deployment.

Residual Aortic Regurgitation and PVL {#jah31553-sec-0019}
-------------------------------------

It is well known that the incidence of PVL is associated with worse short‐ and long‐term outcomes.[25](#jah31553-bib-0025){ref-type="ref"}, [26](#jah31553-bib-0026){ref-type="ref"}, [27](#jah31553-bib-0027){ref-type="ref"} Our results show a higher pooled incidence of PVL with the self‐expanding valve compared with the balloon‐expandable valve, and these percentages remained much higher even if analyzing groups with and without preimplantation BAV separately. Indeed, these results are in line with previously reported evidence.[27](#jah31553-bib-0027){ref-type="ref"}, [28](#jah31553-bib-0028){ref-type="ref"} Interestingly, Fiorina and colleagues[9](#jah31553-bib-0009){ref-type="ref"} reported lower incidence of moderate to severe PVL without preimplantation BAV; however, hemodynamics were not statistically different between the 2 strategies, as assessed by aortic regurgitation index, likely due to low incidence of severe PVL. It is quite provocative to suggest that performing TAVI without preimplantation BAV may reduce PVL, mostly using the self‐expandable valve because of its delivery mechanism, composed of a self‐expanding nitinol frame. Regarding the balloon‐expandable bioprosthesis, PVL reduction might have been related to better understanding of valve sizing (and slight oversizing) that progressed along the same learning curve and led to confidence in direct implantation. In addition, some studies included the SAPIEN 3 bioprosthesis, which includes a specific anti‐PVL sealing design.

Need for Postimplantation Postdilation {#jah31553-sec-0020}
--------------------------------------

According to our results, the self‐expanding valve was associated with a crude 2‐fold greater need for postdilation. Importantly, postimplantation postdilation can also cause device migration and thus increase PVL[9](#jah31553-bib-0009){ref-type="ref"} as well as the risk for annular rupture with postdilation than with predilation. Although avoiding BAV minimizes manipulation of the severely calcified aortic annulus or native valve, it must be balanced with the potential need for more postdilation to correct a significant residual PVL. Furthermore, the impact of postdilation on the long‐term valve outcome remains unknown.

Aortic Valve Calcification Assessment to Plan TAVI Without Preimplantation BAV {#jah31553-sec-0021}
------------------------------------------------------------------------------

The degree and distribution of aortic valve calcification and annular morphology has been correlated with postprocedural PVL.[29](#jah31553-bib-0029){ref-type="ref"}, [30](#jah31553-bib-0030){ref-type="ref"}, [31](#jah31553-bib-0031){ref-type="ref"}, [32](#jah31553-bib-0032){ref-type="ref"} Moreover, the location and/or asymmetry of this calcification, more often located at the noncoronary cusp and/or device landing zone, is more important than the total calcium load.[20](#jah31553-bib-0020){ref-type="ref"}, [29](#jah31553-bib-0029){ref-type="ref"}, [31](#jah31553-bib-0031){ref-type="ref"} Interestingly, Mollmann and colleagues[14](#jah31553-bib-0014){ref-type="ref"} showed no differences in the extent of valve calcification, as assessed by Agatston score, among patients treated with the 2 strategies. In addition, they found no correlation between the aortic valve area and load of calcification with the duration of the procedure, fluoroscopy time, radiation dose, or contrast amount. Similarly, Fiorina et al[9](#jah31553-bib-0009){ref-type="ref"} found no correlation between residual PVL and the degree of calcification in the device landing zone among those who received TAVI without preimplantation BAV. Of note, the authors also reported that among patients who received preimplantation BAV, bigger prosthesis size indicated higher incidence of significant PVL, although that relationship was not observed in patients in which TAVI was undertaken without preimplantation BAV.[9](#jah31553-bib-0009){ref-type="ref"}

Islas and colleagues[17](#jah31553-bib-0017){ref-type="ref"} reported favorable and unfavorable features relevant to the decision to perform TAVI without preimplantation BAV using 3‐dimentional transesophageal echocardiography. Notably, unfavorable features included heavy or severe aortic valve calcification, defined as leaflet thickness \>5 mm with large nodules and diffuse calcification of the aortic annulus; an asymmetric and bulky calcification distribution; valve area \<0.4 cm^2^ with an eccentric and/or irregular orifice; moderately or severely restricted mobility; presence of calcification nodules at the left ventricle outflow tract or close to coronary ostia; and moderate aortic regurgitation. In this regard, Bijuklic et al[20](#jah31553-bib-0020){ref-type="ref"} also reported that in cases of severe asymmetric aortic valve calcification or a tight aortic effective orifice area (planimetry ≤0.5 cm^2^), as assessed by intraprocedural transesophageal echocardiography, preimplantation BAV was performed even if the newest generation lower profile Edwards SAPIEN 3 valve was available.

Neurological Events {#jah31553-sec-0022}
-------------------

It has been hypothesized that TAVI without preimplantation BAV may be associated with fewer embolic events, especially fewer cerebrovascular accidents. Strikingly, relatively low stroke rates have been reported with the 2 strategies and the 2 TAVI devices. The different technique by which the balloon‐expandable valve is deployed, more often oversized, compared with the self‐expandable valve (less aggressive expansion technique) may explain the higher potential for calcific embolization. In this regard, the new‐generation balloon‐expandable Edwards SAPIEN 3 valve requires less overexpansion compared with the SAPIEN XT; however, most of the analyzed studies failed to support avoiding a preimplantation BAV strategy with reduced neurological complications. Moreover, Aggarwal and colleagues[12](#jah31553-bib-0012){ref-type="ref"} reported no differences between groups in terms of embolic load based on transcranial Doppler, including number in solid, gaseous, or total emboli (*P*\>0.05 for all). In addition, Bijuklic et al[20](#jah31553-bib-0020){ref-type="ref"} showed no difference in terms of silent embolic events assessed by diffusion‐weighted cerebral magnetic resonance. Interestingly, a large volume was observed among those undergoing TAVI without preimplantation BAV. Importantly, the authors reported that 4 patients experienced stroke, 3 of them without preimplantation BAV and 1 patient with preimplantation BAV. Nonetheless, because of the exclusion criteria stated in the methodology, these patients were excluded from analysis because of a clinically apparent stroke within 3 days after TAVI.[20](#jah31553-bib-0020){ref-type="ref"}

Potential Benefits of TAVI Without Preimplantation BAV {#jah31553-sec-0023}
------------------------------------------------------

Preimplantation BAV might be poorly tolerated by certain patients. The time between BAV predilation and TAVI is a particularly crucial period, especially in patients with preexisting severe left ventricular systolic dysfunction and/or pulmonary hypertension. Moreover, the temporary interruption in ventricular output during rapid ventricular pacing and BAV outflow occlusion itself can result in hemodynamic compromise. Furthermore, significant aortic regurgitation following BAV can precipitate clinically important instability, even in patients with normal left ventricular function; this hemodynamic deterioration can be sudden, profound, and not entirely predictable. The special subset of patients presenting with and/or prone to hemodynamic instability can experience multiorgan hypoperfusion, mainly cerebral and renal; therefore, avoiding a rapid pacing run for BAV may prevent an unnecessary period of hypotension in certain cases.

Alternatively, it is logical that performing TAVI without preimplantation BAV is associated with a reduction in contrast volume,[6](#jah31553-bib-0006){ref-type="ref"}, [11](#jah31553-bib-0011){ref-type="ref"}, [14](#jah31553-bib-0014){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"}, [20](#jah31553-bib-0020){ref-type="ref"} fluoroscopy time,[12](#jah31553-bib-0012){ref-type="ref"}, [16](#jah31553-bib-0016){ref-type="ref"}, [18](#jah31553-bib-0018){ref-type="ref"} radiation dose,[14](#jah31553-bib-0014){ref-type="ref"} or total procedural time.[6](#jah31553-bib-0006){ref-type="ref"}, [17](#jah31553-bib-0017){ref-type="ref"}, [20](#jah31553-bib-0020){ref-type="ref"} The clinical impact of these differences is uncertain.

Limitations {#jah31553-sec-0024}
-----------

The present study has several limitations. The main limitation lies with the small number of patients within each study and the nonrandomized nature of the included studies that may introduce selection bias. Importantly, the decision of whether or not to predilate was made at the discretion of the TAVI team operator and may relate to the complexity of the valve anatomy and the operator\'s perception of successful valve delivery; therefore, it is possible that BAV was undertaken in more complex and challenging cases, subjecting comparison of outcomes to selection bias. In addition, patient‐level data were not available for this analysis, precluding more robust adjustment for any differences in clinical or anatomical variables. Nevertheless, in studies that reported clinical demographics and anatomical features of the patients, these variables were relatively well matched in both BAV/non‐BAV studied cohorts. Notably, many of the studies included in this analysis lacked data on whether patients had hemodynamic compromise and/or poor left ventricle function necessitating BAV prior to the index TAVI procedure (bridge to TAVI). Finally, patients exhibiting major comorbidities and clinically uncertain benefit from TAVI may have been offered BAV as a potential bridge or palliation due to an adverse profile, with subsequent definitive treatment (TAVI) offered after substantial improvement.

Conclusion {#jah31553-sec-0025}
==========

Our analysis suggests that TAVI procedures with or without preimplantation BAV were associated with similar outcomes for a number of clinically relevant end points. Further studies including large number of patients are needed to ascertain the impact of TAVI without preimplantation BAV as a standard practice. Meanwhile, our findings provide real‐world data that may contribute to the current practice of TAVI operators and influence future perspectives. Notably, a simplified procedure can be safely performed and achieve comparable results.
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